• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Labcorp Holdings Inc.

    5/29/25 4:05:23 PM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email
    S-8 POS 1 d856036ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on May 29, 2025

    Registration No. 333-279514

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-8

    REGISTRATION STATEMENT (333-279514)

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Labcorp Holdings Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   99-2588107

    (State or other jurisdiction of

    incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    358 South Main Street, Burlington, North Carolina   27215
    (Address of Principal Executive Offices)   (Zip Code)

    Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan

    (Full titles of the plans)

    Sandra D. van der Vaart

    Executive Vice President, Chief Legal Officer and Corporate Secretary

    Labcorp Holdings Inc.

    358 South Main Street

    Burlington, North Carolina 27215

    (Name and address of agent for service)

    (336) 229-1127

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    William I. Intner

    Hogan Lovells US LLP

    100 International Drive, Suite 2000

    Baltimore, Maryland 21202

    (410) 659-2700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment No. 1”) relates to the Registration Statement on Form S-8 (File No. 333-279514) (the “Registration Statement”) filed with the Securities and Exchange Commission by Labcorp Holdings Inc. (the “Company”) and is being filed to deregister only those shares of the Company’s common stock, par value $0.10 per share (“Common Stock”), issuable pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan (the “Plan”) that were registered under the Registration Statement and remain unissued or unsold thereunder.

    The Company is no longer offering its securities under the Plan. Thus, in accordance with an undertaking made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offering, the Company hereby removes from registration any shares of Common Stock registered under the Registration Statement issuable pursuant to the Plan which remain unissued or unsold as of May 15, 2025. Although any shares of Common Stock issuable pursuant to the Plan are being deregistered, this Post-Effective Amendment No. 1 shall not serve to reduce the number of shares of Common Stock covered by the Registration Statement and issuable pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Burlington, State of North Carolina, on May 29, 2025.

     

    LABCORP HOLDINGS INC.
    By:  

    /s/ Sandra D. van der Vaart

      Sandra D. van der Vaart
      Executive Vice President, Chief Legal Officer and Corporate Secretary

    No other person is required to sign this Post-Effective Amendment No. 1 in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $LH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    2/26/2024$260.00Outperform
    Leerink Partners
    More analyst ratings

    $LH
    Financials

    Live finance-specific insights

    See more
    • Labcorp Announces 2025 First Quarter Results

      Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year:Revenue: $3.35 billion versus $3.18 billionDiluted EPS: $2.52 versus $2.69Adjusted EPS: $3.84 versus $3.68Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS:Revenue guidance of 6.7% to 8.0%Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05Free Cash Flow of $1.10 billion to $1.25 billionProviding broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-dateIntroduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid

      4/29/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Declares Quarterly Dividend

      BURLINGTON, N.C., April 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2025, to stockholders of record as of the close of business on May 29, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confid

      4/10/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp to Announce First Quarter Financial Results on April 29, 2025

      BURLINGTON, N.C., March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan

      3/31/25 4:15:00 PM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Leadership Updates

    Live Leadership Updates

    See more
    • SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

      SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv

      5/12/25 9:00:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

      Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

      11/19/24 7:00:00 AM ET
      $BGNE
      $LH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

      Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

      10/18/24 9:00:00 AM ET
      $ENV
      $LH
      $MASI
      $MSCI
      Business Services
      Consumer Discretionary
      Medical Specialities
      Health Care

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Schechter Adam H sold $1,518,497 worth of shares (6,105 units at $248.73), decreasing direct ownership by 6% to 98,962 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      5/13/25 10:01:55 AM ET
      $LH
      Medical Specialities
      Health Care
    • EVP, Chief Legal Officer Van Der Vaart Sandra D sold $452,884 worth of shares (1,900 units at $238.36), decreasing direct ownership by 46% to 2,244 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      5/5/25 12:45:59 PM ET
      $LH
      Medical Specialities
      Health Care
    • SVP, Chief Accounting Officer Wilkinson Peter J sold $200,838 worth of shares (829 units at $242.26), decreasing direct ownership by 29% to 2,054 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      5/5/25 12:45:10 PM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

      Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

      4/2/25 8:50:29 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. upgraded by Citigroup with a new price target

      Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

      3/4/25 7:36:42 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Labcorp Holdings Inc. from In-line to Outperform and set a new price target of $265.00 from $260.00 previously

      1/7/25 8:12:52 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    SEC Filings

    See more
    • SEC Form SD filed by Labcorp Holdings Inc.

      SD - LABCORP HOLDINGS INC. (0000920148) (Filer)

      5/30/25 11:18:20 AM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by Labcorp Holdings Inc.

      S-8 - LABCORP HOLDINGS INC. (0000920148) (Filer)

      5/29/25 4:09:57 PM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Labcorp Holdings Inc.

      S-8 POS - LABCORP HOLDINGS INC. (0000920148) (Filer)

      5/29/25 4:05:23 PM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

      New test offerings target solid tumors and hematologic malignancies Enhanced biopharma services support accelerated clinical trials and companion diagnostic development BURLINGTON, N.C., May 30, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma solutions designed to accelerate clinical trials and companion diagnostic development. "Labcorp is comm

      5/30/25 7:00:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

      SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv

      5/12/25 9:00:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp to Webcast Its Annual Meeting of Shareholders May 15

      BURLINGTON, N.C., May 8, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 15 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website. An archived replay of the webcast will be available for one year. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident dec

      5/8/25 4:15:00 PM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

      SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

      2/13/24 5:08:06 PM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Laboratory Corporation of America Holdings (Amendment)

      SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)

      7/24/23 4:20:26 PM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

      2/10/21 11:14:27 AM ET
      $LH
      Medical Specialities
      Health Care